Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actinium Pharmaceuticals(US:ATNM) Prnewswire·2025-10-13 20:30-  ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression levels -  Extended follow-up in prostate cancer models demonstrated durable anti-tumor responses with ATNM- 400, exceeding those achieved with the androgen receptor pathway inhibitor (ARPI), enzalutamide , /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pio ...